One-carbon Therapeutics
One-carbon Therapeutics AB is a clinical-stage biotechnology company pioneering novel anti-cancer therapies. Based on the strong preclinical data for TH9619 - first-in-class, potent, small molecule and dual inhibitor of MTHFD1/2 - One-carbon Therapeutics is targeting difficult to treat advanced refractory solid tumors. The company is headquartered in Sweden and is committed to translating cutting-edge metabolic science into transformative clinical impact for subjects worldwide.Content by One-carbon Therapeutics
| 2 min read
The new investment accelerates development of a potential breakthrough therapy targeting the one-carbon metabolic pathway.
Page 1 of 1 - 1 Total Items
